OBJECTIVES: The National Institute for Health and Care Excellence (NICE) and Scottish Medicines Consortium (SMC) are technology assessment bodies that issue guidance on whether health technologies should be adopted by their respective health systems (NICE: England and Wales, SMC: Scotland) based upon their clinical- and cost-effectiveness. This research aims to compare how acceptance rates between NICE and SMC have varied over time. METHODS: All NICE Single Technology Appraisal (STA) and SMC appraisal outcomes were screened up to 31^st November 2015. The drug, date, and outcome were extracted. Statistical analyses were performed using Pearson’s correlation coefficient. RESULTS: CONCLUSIONS: The SMC are issuing a significantly higher percentage of positive recommendations in more recent years. This may be linked to the new Patient and Clinician Engagement Group (PACE) process introduced in 2014, enabling more flexible consideration of ICERs by the SMC.